Streptococcus suis is not only a pathogenic bacterium that impacts swine production, but it also is a zoonotic agent responsible for an increasing number of human infections in recent years. Preventative treatment of swine herds with vaccines has resulted in relatively low levels of protection. Pigs may also be administered antibiotics, usually of a medically important class, to control infection. Despite the effectiveness of antibiotics for disease prevention, there is pressure to reduce use of these agents in pig farming. Therefore, Elanco desires novel approaches to prevent, treat, or control S. suis infection in swine.
*** Webinar *** An online webinar presented by Elanco and InnoCentive concerning Elanco's Grand Challenge Program will be held on October 20, 2016 at 10:30 AM (US Eastern Time). The webinar will include a question and answer session. Register in advance here: https://innocentive.webex.com/innocentive/j.php?RGID=re71ea91971dce8a5bd40cbb6d0d0b74c.
After registering, you will receive a confirmation email with a link to join the webinar. A recording will be attached to this Challenge for those who are unable to attend.
This Theoretical Challenge requires only a written proposal.
Primarily infecting swine and humans, Streptococcus suis has occasionally been identified in companion and other food animals. Mainly residing in the upper respiratory tract of pigs, this Gram-positive pathogen is associated with meningitis, arthritis, pneumonia, and mortality. S. suis infection of piglets occurs directly from the sow whereas transmission in older animals occurs through respiratory secretions. A total of 35 serotypes have been described, and it is this diversity that makes it difficult to produce a vaccine that offers cross-protection against multiple strains. Therefore, Elanco desires novel approaches to prevent, treat, or control S. suis infection in swine.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rights to the solution.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on October 23, 2016.
Late submissions will not be considered.
ABOUT THE SEEKER
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for nearly 7,000 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Elanco has committed to an 8-step Antibiotic Stewardship Plan that ensures the responsible use of antibiotics, reduces shared-class antibiotic use, and replaces antibiotics with alternatives. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com and EnoughMovement.com.
What is a Theoretical IP Transfer Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-IP Transfer Challenge, meaning that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. By contrast, Theoretical-Licensing means that the Seeker is requesting non-exclusive rights to use the winning solution. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.